Medical virtual reality company XR Health has acquired Swing Therapeutics, a developer specializing in digital treatments for fibromyalgia. The transaction marks a strategic move by XR Health to solidify its position as a leading provider of therapeutic digital care.
Strategic Implications and Company Overview
Swing Therapeutics was known for developing a digital treatment regimen for fibromyalgia that had received clearance from the Food and Drug Administration (FDA). With this purchase, Swing becomes the sixth company acquired by XR Health within the past two years, indicating a major shift in the virtual reality developer’s business focus towards comprehensive disease management through digital modalities.
Details regarding the financial terms of the acquisition were not released. According to Eran Orr, CEO of XR Health, the specific figures remain confidential because he indicated that this will likely not be the last corporate acquisition for the firm.
XR Health’s Digital Care Ecosystem
XR Health currently operates a platform featuring dozens of diverse applications designed to address various health conditions. The company reported achieving one million user sessions during 2025 alone. Its current offerings include a wide array of virtual reality experiences based on principles of meditation and cognitive behavioral therapy (CBT). These programs are tailored for managing mental health issues, chronic pain, hot flashes, and other related conditions.
While XR Health’s comprehensive packages of VR treatments are registered with the FDA, it is important to note that they have not yet received full clearance from regulatory bodies. During an explanation of the company’s growth trajectory, Eran Orr stated: “it won’t be the last” acquisition for the company.
